+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Fosaprepitant Dimeglumine for Injection Market - Global Forecast 2025-2030- Product Image
Fosaprepitant Dimeglumine for Injection Market - Global Forecast 2025-2030- Product Image
Sale

Fosaprepitant Dimeglumine for Injection Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 181 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6133438
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Fosaprepitant dimeglumine for injection is transforming chemotherapy-induced nausea and vomiting (CINV) management, driving a pivotal shift toward streamlined and reliable intravenous antiemetic therapy across advanced oncology settings. This report offers critical market intelligence for stakeholders aiming to understand changing clinical preferences, regulatory environments, and supply dynamics affecting decision-making in CINV supportive care.

Market Snapshot

The global fosaprepitant dimeglumine market is witnessing robust expansion, underpinned by the increasing adoption of intravenous antiemetics in oncology protocols and a growing emphasis on patient-centric cancer care delivery. Market participants are responding to evolving therapeutic guidelines and payer scrutiny, adapting their commercial strategies in response to the latest trade policies and regulatory frameworks. As the market landscape adapts to new supply chain realities and the rising burden of cancer worldwide, leaders must anticipate shifting stakeholder expectations and capitalize on emerging growth areas.

Scope & Segmentation

This report delivers thorough segmentation and trend analysis, enabling targeted insights across the entire value chain.

  • End Users: Cancer centers, clinics, home care units, hospitals
  • Distribution Channels: Hospital pharmacies, online pharmacies, retail pharmacies, specialty pharmacies
  • Application Phases: Acute phase, delayed phase
  • Patient Groups: Adult, geriatric, pediatric
  • Regional Markets: Americas, Europe Middle East & Africa, Asia-Pacific
  • Key Geographies: United States (California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio), Canada, Mexico, Brazil, Argentina, United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland, China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan
  • Leading Companies: Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Viatris Inc., Apotex Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Fresenius Kabi AG, Accord Healthcare Ltd.

Key Takeaways

  • Fosaprepitant dimeglumine delivers rapid and sustained plasma concentrations of aprepitant, improving antiemetic coverage and ensuring alignment with hospital intravenous protocols.
  • Intravenous regimens advance workflow efficiency in high-volume cancer treatment centers, supporting predictable patient adherence compared to multi-day oral dosing.
  • Value-based oncology models are driving an increased focus on therapies that balance clinical performance with cost containment and patient quality of life.
  • Growing generic competition and patent expiries are reshaping the competitive landscape, prompting originators and new entrants to seek co-marketing and expanded manufacturing strategies.
  • Segmented adoption patterns highlight the importance of tailored dosing and formulation adjustments to address the needs of adults, elderly, and pediatric populations.
  • Strategic alliances, including licensing and clinical collaboration, are enabling broader regional reach and fostering robust real-world evidence generation to support reimbursement efforts.

Tariff Impact on Supply Chain and Cost Structure

The newly enacted United States tariffs for 2025 are increasing pressures on the supply chain and procurement strategies for fosaprepitant dimeglumine. Manufacturers are reconsidering sourcing and localizing production to mitigate tariff exposures, while distributors and institutions implement volume-based agreements to stabilize costs and maintain consistent access. These adaptations aim to ensure the continuity of care for patients needing intravenous antiemetics despite evolving policy landscapes.

Methodology & Data Sources

Research for this analysis integrates primary interviews with oncologists, pharmacists, and procurement leads across key regions with secondary assessment of clinical trials, regulatory documentation, and white papers. Findings were triangulated using proprietary datasets and governmental resources to ensure that both qualitative insights and quantifiable data support robust strategic recommendations.

Why This Report Matters

  • Enables senior decision-makers to benchmark evolving competitive strategies and understand cross-regional adoption drivers for fosaprepitant dimeglumine therapy portfolios.
  • Delivers actionable insights on optimizing procurement, responding to tariff impacts, and capitalizing on segmentation opportunities across diverse end-user environments.

Conclusion

Fosaprepitant dimeglumine for injection is set to redefine antiemetic standards by aligning clinical advances with operational resilience and regional expansion. Institutions and suppliers that prioritize targeted innovation and evidence-backed positioning will remain at the forefront in a rapidly changing CINV therapeutic landscape.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Market uptake of intravenous NK-1 receptor antagonists in chemotherapy-induced nausea and vomiting prophylaxis
5.2. Impact of patent expiry and emerging generics on fosaprepitant dimeglumine pricing dynamics and reimbursement negotiations
5.3. Shift towards combination antiemetic regimens integrating fosaprepitant with 5-HT3 antagonists and corticosteroids in oncology care pathways
5.4. Strategic alliances between pharmaceutical companies and hospital networks to optimize fosaprepitant dimeglumine distribution and inventory management
5.5. Investigation of real-world outcomes and adherence rates of single-dose fosaprepitant injections in outpatient oncology settings
5.6. Expansion of fosaprepitant indications into radiation-induced nausea and vomiting following favorable clinical trial results
5.7. Supply chain resilience strategies addressing raw material shortages and manufacturing bottlenecks for fosaprepitant production
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Fosaprepitant Dimeglumine for Injection Market, by End User
8.1. Introduction
8.2. Cancer Centers
8.3. Clinics
8.4. Home Care Units
8.5. Hospitals
9. Fosaprepitant Dimeglumine for Injection Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies
9.5. Specialty Pharmacies
10. Fosaprepitant Dimeglumine for Injection Market, by Application Phase
10.1. Introduction
10.2. Acute Phase
10.3. Delayed Phase
11. Fosaprepitant Dimeglumine for Injection Market, by Patient Group
11.1. Introduction
11.2. Adult
11.3. Geriatric
11.4. Pediatric
12. Americas Fosaprepitant Dimeglumine for Injection Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Fosaprepitant Dimeglumine for Injection Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Fosaprepitant Dimeglumine for Injection Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Merck & Co., Inc.
15.3.2. Teva Pharmaceutical Industries Ltd.
15.3.3. Sandoz International GmbH
15.3.4. Viatris Inc.
15.3.5. Apotex Inc.
15.3.6. Pfizer Inc.
15.3.7. Sun Pharmaceutical Industries Ltd.
15.3.8. Dr. Reddy’s Laboratories Ltd.
15.3.9. Fresenius Kabi AG
15.3.10. Accord Healthcare Ltd.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 6. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 8. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2024 VS 2030 (%)
FIGURE 12. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET: RESEARCHAI
FIGURE 24. FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET: RESEARCHSTATISTICS
FIGURE 25. FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET: RESEARCHCONTACTS
FIGURE 26. FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY CANCER CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY HOME CARE UNITS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY HOME CARE UNITS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY ACUTE PHASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY ACUTE PHASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DELAYED PHASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DELAYED PHASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. AMERICAS FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 44. AMERICAS FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 45. AMERICAS FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 46. AMERICAS FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 47. AMERICAS FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2018-2024 (USD MILLION)
TABLE 48. AMERICAS FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2025-2030 (USD MILLION)
TABLE 49. AMERICAS FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 50. AMERICAS FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 51. AMERICAS FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 52. AMERICAS FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 53. UNITED STATES FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 54. UNITED STATES FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 55. UNITED STATES FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 56. UNITED STATES FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 57. UNITED STATES FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2018-2024 (USD MILLION)
TABLE 58. UNITED STATES FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2025-2030 (USD MILLION)
TABLE 59. UNITED STATES FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 60. UNITED STATES FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 61. UNITED STATES FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 62. UNITED STATES FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 63. CANADA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 64. CANADA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 65. CANADA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 66. CANADA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 67. CANADA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2018-2024 (USD MILLION)
TABLE 68. CANADA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2025-2030 (USD MILLION)
TABLE 69. CANADA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 70. CANADA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 71. MEXICO FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 72. MEXICO FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 73. MEXICO FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 74. MEXICO FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 75. MEXICO FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2018-2024 (USD MILLION)
TABLE 76. MEXICO FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2025-2030 (USD MILLION)
TABLE 77. MEXICO FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 78. MEXICO FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 79. BRAZIL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 80. BRAZIL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 81. BRAZIL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 82. BRAZIL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 83. BRAZIL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2018-2024 (USD MILLION)
TABLE 84. BRAZIL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2025-2030 (USD MILLION)
TABLE 85. BRAZIL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 86. BRAZIL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 87. ARGENTINA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 88. ARGENTINA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 89. ARGENTINA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 90. ARGENTINA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 91. ARGENTINA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2018-2024 (USD MILLION)
TABLE 92. ARGENTINA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2025-2030 (USD MILLION)
TABLE 93. ARGENTINA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 94. ARGENTINA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2018-2024 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2025-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 106. UNITED KINGDOM FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 107. UNITED KINGDOM FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 108. UNITED KINGDOM FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2018-2024 (USD MILLION)
TABLE 110. UNITED KINGDOM FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2025-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 112. UNITED KINGDOM FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 113. GERMANY FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 114. GERMANY FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 115. GERMANY FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 116. GERMANY FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 117. GERMANY FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2018-2024 (USD MILLION)
TABLE 118. GERMANY FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2025-2030 (USD MILLION)
TABLE 119. GERMANY FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 120. GERMANY FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 121. FRANCE FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 122. FRANCE FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 123. FRANCE FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 124. FRANCE FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 125. FRANCE FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2018-2024 (USD MILLION)
TABLE 126. FRANCE FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2025-2030 (USD MILLION)
TABLE 127. FRANCE FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 128. FRANCE FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 129. RUSSIA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 130. RUSSIA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 131. RUSSIA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. RUSSIA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. RUSSIA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2018-2024 (USD MILLION)
TABLE 134. RUSSIA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2025-2030 (USD MILLION)
TABLE 135. RUSSIA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 136. RUSSIA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 137. ITALY FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 138. ITALY FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 139. ITALY FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 140. ITALY FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 141. ITALY FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2018-2024 (USD MILLION)
TABLE 142. ITALY FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2025-2030 (USD MILLION)
TABLE 143. ITALY FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 144. ITALY FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 145. SPAIN FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 146. SPAIN FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 147. SPAIN FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. SPAIN FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. SPAIN FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2018-2024 (USD MILLION)
TABLE 150. SPAIN FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2025-2030 (USD MILLION)
TABLE 151. SPAIN FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 152. SPAIN FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 153. UNITED ARAB EMIRATES FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 154. UNITED ARAB EMIRATES FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 155. UNITED ARAB EMIRATES FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 156. UNITED ARAB EMIRATES FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 157. UNITED ARAB EMIRATES FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2018-2024 (USD MILLION)
TABLE 158. UNITED ARAB EMIRATES FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2025-2030 (USD MILLION)
TABLE 159. UNITED ARAB EMIRATES FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 160. UNITED ARAB EMIRATES FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 162. SAUDI ARABIA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. SAUDI ARABIA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. SAUDI ARABIA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2018-2024 (USD MILLION)
TABLE 166. SAUDI ARABIA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2025-2030 (USD MILLION)
TABLE 167. SAUDI ARABIA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 168. SAUDI ARABIA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 169. SOUTH AFRICA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 170. SOUTH AFRICA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 171. SOUTH AFRICA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. SOUTH AFRICA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. SOUTH AFRICA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2018-2024 (USD MILLION)
TABLE 174. SOUTH AFRICA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2025-2030 (USD MILLION)
TABLE 175. SOUTH AFRICA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 176. SOUTH AFRICA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 177. DENMARK FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 178. DENMARK FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 179. DENMARK FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. DENMARK FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 181. DENMARK FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2018-2024 (USD MILLION)
TABLE 182. DENMARK FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2025-2030 (USD MILLION)
TABLE 183. DENMARK FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 184. DENMARK FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 185. NETHERLANDS FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 186. NETHERLANDS FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 187. NETHERLANDS FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 188. NETHERLANDS FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 189. NETHERLANDS FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2018-2024 (USD MILLION)
TABLE 190. NETHERLANDS FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2025-2030 (USD MILLION)
TABLE 191. NETHERLANDS FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 192. NETHERLANDS FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 193. QATAR FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 194. QATAR FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 195. QATAR FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 196. QATAR FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 197. QATAR FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2018-2024 (USD MILLION)
TABLE 198. QATAR FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2025-2030 (USD MILLION)
TABLE 199. QATAR FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 200. QATAR FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 201. FINLAND FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 202. FINLAND FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 203. FINLAND FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 204. FINLAND FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 205. FINLAND FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2018-2024 (USD MILLION)
TABLE 206. FINLAND FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2025-2030 (USD MILLION)
TABLE 207. FINLAND FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 208. FINLAND FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 209. SWEDEN FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 210. SWEDEN FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 211. SWEDEN FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 212. SWEDEN FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 213. SWEDEN FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2018-2024 (USD MILLION)
TABLE 214. SWEDEN FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2025-2030 (USD MILLION)
TABLE 215. SWEDEN FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 216. SWEDEN FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 217. NIGERIA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 218. NIGERIA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 219. NIGERIA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 220. NIGERIA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 221. NIGERIA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2018-2024 (USD MILLION)
TABLE 222. NIGERIA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2025-2030 (USD MILLION)
TABLE 223. NIGERIA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 224. NIGERIA FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 225. EGYPT FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 226. EGYPT FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 227. EGYPT FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 228. EGYPT FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 229. EGYPT FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2018-2024 (USD MILLION)
TABLE 230. EGYPT FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2025-2030 (USD MILLION)
TABLE 231. EGYPT FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 232. EGYPT FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 233. TURKEY FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 234. TURKEY FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 235. TURKEY FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 236. TURKEY FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 237. TURKEY FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2018-2024 (USD MILLION)
TABLE 238. TURKEY FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2025-2030 (USD MILLION)
TABLE 239. TURKEY FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 240. TURKEY FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 241. ISRAEL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 242. ISRAEL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 243. ISRAEL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 244. ISRAEL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 245. ISRAEL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2018-2024 (USD MILLION)
TABLE 246. ISRAEL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2025-2030 (USD MILLION)
TABLE 247. ISRAEL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 248. ISRAEL FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 249. NORWAY FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 250. NORWAY FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 251. NORWAY FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 252. NORWAY FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 253. NORWAY FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2018-2024 (USD MILLION)
TABLE 254. NORWAY FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2025-2030 (USD MILLION)
TABLE 255. NORWAY FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 256. NORWAY FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 257. POLAND FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 258. POLAND FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 259. POLAND FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 260. POLAND FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 261. POLAND FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2018-2024 (USD MILLION)
TABLE 262. POLAND FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2025-2030 (USD MILLION)
TABLE 263. POLAND FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 264. POLAND FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 265. SWITZERLAND FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 266. SWITZERLAND FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 267. SWITZERLAND FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 268. SWITZERLAND FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 269. SWITZERLAND FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2018-2024 (USD MILLION)
TABLE 270. SWITZERLAND FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2025-2030 (USD MILLION)
TABLE 271. SWITZERLAND FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 272. SWITZERLAND FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 273. ASIA-PACIFIC FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 274. ASIA-PACIFIC FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 275. ASIA-PACIFIC FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 276. ASIA-PACIFIC FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 277. ASIA-PACIFIC FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2018-2024 (USD MILLION)
TABLE 278. ASIA-PACIFIC FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY APPLICATION PHASE, 2025-2030 (USD MILLION)
TABLE 279. ASIA-PACIFIC FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 280. ASIA-PACIFIC FOSAPREPITANT DIMEGLUMINE FOR INJECTION MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 281. ASIA-PACIFIC FOSAPREPITANT DIMEGLUMINE

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Fosaprepitant Dimeglumine for Injection market report include:
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Viatris Inc.
  • Apotex Inc.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy’s Laboratories Ltd.
  • Fresenius Kabi AG
  • Accord Healthcare Ltd.

Related Topics

Related Reports

Fosaprepitant Dimeglumine (CAS 265121-04-8) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Fosaprepitant Dimeglumine (CAS 265121-04-8) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Fosaprepitant (CAS 172673-20-0) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Fosaprepitant (CAS 172673-20-0) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Esketamine Hydrochloride Injection Market - Global Forecast 2025-2030 - Product Image

Esketamine Hydrochloride Injection Market - Global Forecast 2025-2030

  • Report
  • 185 Pages
  • Global
From
Gadoxetic Acid Disodium Injection Market - Global Forecast 2025-2030 - Product Image

Gadoxetic Acid Disodium Injection Market - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Self-injection Devices Market Size, Share & Trends Analysis By Product (Auto Injectors, Pen Injectors), By Usability (Disposable, Reusable), By Application (Cancer, Autoimmune Disorders, Hormonal Disorders), By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Self-injection Devices Market Size, Share & Trends Analysis By Product (Auto Injectors, Pen Injectors), By Usability (Disposable, Reusable), By Application (Cancer, Autoimmune Disorders, Hormonal Disorders), By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 120 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.